Rigel Pharmaceuticals Inc. registered with regulators for a stock sale worth up to $25 million.
The South San Francisco company (NASDAQ: RIGL) is working on a treatment for rheumatoid arthritis along with AstraZeneca AB, and also an inhaled treatment for allergic asthma.
No comments:
Post a Comment